Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone.

Lee JT, Kroemer HK, Silberstein DJ, Funck-Brentano C, Lineberry MD, Wood AJ, Roden DM, Woosley RL.

N Engl J Med. 1990 Jun 21;322(25):1764-8.

2.
3.

Clinical pharmacology and beta-blocking efficacy of propafenone.

Barbey JT.

J Cardiovasc Pharmacol. 1991;17 Suppl 6:S41-3. Review.

PMID:
1723117
4.

An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy.

Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M.

Circulation. 1994 May;89(5):2396-400.

PMID:
7910120
6.

Stereoselective disposition and pharmacologic activity of propafenone enantiomers.

Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM.

Circulation. 1989 May;79(5):1068-76.

PMID:
2713973
9.

Polymorphic metabolism of beta-adrenoceptor antagonists.

Silas JH, Lennard MS, Tucker GT, Ramsay LE, Woods HF.

Br J Clin Pharmacol. 1984;17 Suppl 1:11S-19S.

10.

Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.

Laurent-Kenesi MA, Funck-Brentano C, Poirier JM, Decolin D, Jaillon P.

Br J Clin Pharmacol. 1993 Dec;36(6):531-8.

11.

Beta-adrenoceptor blocking activity of diprafenone in anesthetized dogs: comparison with propafenone and propranolol.

Greenberg S, Cantor E, Paul J.

J Cardiovasc Pharmacol. 1989 Sep;14(3):444-53.

PMID:
2476625
12.

Lack of clinically significant beta-blocking effect of propafenone.

Cheriex EC, Krijne R, Brugada P, Heymeriks J, Wellens HJ.

Eur Heart J. 1987 Jan;8(1):53-6.

PMID:
2880719
13.

Experimental evidence for beta adrenergic blocking properties of propafenone and for their potential clinical relevance.

Malfatto G, Pessano P, Zaza A, Schwartz PJ.

Eur Heart J. 1993 Sep;14(9):1253-7.

PMID:
7901020
14.

Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response.

Sowinski KM, Burlew BS.

Pharmacotherapy. 1997 Nov-Dec;17(6):1305-10.

PMID:
9399616
16.

Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol.

Lennard MS, Tucker GT, Silas JH, Woods HF.

Xenobiotica. 1986 May;16(5):435-47.

PMID:
2874665
17.

Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.

Funck-Brentano C, Kroemer HK, Pavlou H, Woosley RL, Roden DM.

Br J Clin Pharmacol. 1989 Apr;27(4):435-44.

18.

Different stereoselective effects of (R)- and (S)-propafenone: clinical pharmacologic, electrophysiologic, and radioligand binding studies.

Stoschitzky K, Klein W, Stark G, Stark U, Zernig G, Graziadei I, Lindner W.

Clin Pharmacol Ther. 1990 Jun;47(6):740-6.

PMID:
2162749
19.

Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6.

Dilger K, Greiner B, Fromm MF, Hofmann U, Kroemer HK, Eichelbaum M.

Pharmacogenetics. 1999 Oct;9(5):551-9.

PMID:
10591535
20.

Assessment of beta-adrenoceptor selectivity of a new beta-adrenoceptor antagonist, bisoprolol, in man.

Tattersfield AE, Cragg DJ, Bacon RJ.

Br J Clin Pharmacol. 1984 Sep;18(3):343-7.

Supplemental Content

Support Center